Search PubMed⌕ Search

PubMed · 12921116

Superlite Plasma Collection System.

Abstract

The Japanese Ministry of Health, Labor and Welfare launched a national initiative to become plasma self-sufficient by reducing reliance on imported plasma products and increasing plasma collections to enable plasma-derived pharmaceuticals, including albumin, globulin, and Factor VIII products to use plasma collected within Japan. In order to realize this goal, plasma collections from volunteer donors must increase to about 1.5 million litres of plasma per year (1) or about 50% more than what the Japan Red Cross currently collects. A mobile device, such as the Superlite system, will make it easier and more efficient for Japan's sole blood collection agency, the Japan Red Cross, to add plasma collection to mobile blood drives. Haemonetics Corporation (Braintree, MA, USA) has combined many years of apheresis experience with up-to-date technology to create the Superlite Plasma Collection System (PCS) for the Japan Red Cross. This new device, which is expected to greatly contribute to the Red Cross's national source plasma collection program, is even smaller than the Ultralite PCS and offers several advanced features and benefits. Light, compact, and very portable, the Superlite has a Japanese language friendly user interface that continually displays collection status, including time remaining in the collection procedure. The device features a protocol that limits extra-corporeal blood volume for low-weight donors; a program used in conjunction with a reduced volume disposable bowl. Superlite, designed for use in both fixed-site and mobile applications, combines the portable ease-of-use of the Ultralite with the collection process calculation abilities of the CCS to provide a state-of-the-art collection device that will help define the future of Japan plasma collection.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Sohachi Yamazaki. 2003. Superlite Plasma Collection System.. https://doi.org/10.1046/j.1526-0968.2003.00015.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Autologous serum therapy of the ocular surface with novel delivery by platelet concentrate gel.

Application of autologous serum to treat a multitude of ocular surface diseases and conditions is a relatively new technique that has gained popularity over the past 10 years. This review focuses on the use of topical autologous serum and a new platelet gel delivery technique that utilizes autologous platelet concentrate mixed with calcium chloride and thrombin for gelling serum, which can then be applied easily to the corneal surface. Residual platelet serum concentrate can be mixed with artificial tears that are capable of gelling in a 25% concentrate, which is then used by the patient postoperatively. A review of the literature identifies various concentrations of autologous serum, frequency of application, and storage criteria.

Blood Transfusion, Autologous↗

Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRIM).

BACKGROUND: An increased risk of postoperative infection (including pneumonia) attributable to the receipt of allogeneic blood transfusion has been investigated as a possible manifestation of transfusion-related immunomodulation (TRIM) in 16 randomized controlled trials (RCTs) and approximately 40 observational studies. OBJECTIVES: This review categorizes RCTs and observational studies with regard to the inference that they permit about possible mediators of TRIM-allogeneic white cells (WBCs), WBC-derived soluble mediators, and/or allogeneic plasma-and examines whether the totality of the clinical evidence supports an association between allogeneic blood transfusion and postoperative infection. RESULTS: When all available studies are considered together in meta-analyses, three types of studies show no increased risk of postoperative infection in association with allogeneic blood transfusion: a) RCTs comparing recipients of buffy-coat-reduced and prestorage-filtered, WBC-reduced allogeneic red cells; b) RCTs comparing recipients of allogeneic and autologous blood; and c) observational studies comparing patients transfused before and after implementation of WBC reduction. RCTs comparing recipients of nonbuffy-coat-reduced and WBC-reduced red blood cells may point to a TRIM effect, but they cannot yet be subjected to formal meta-analysis. CONCLUSIONS: No overwhelming clinical evidence has been presented to establish the existence of a TRIM effect that relates allogeneic blood transfusion to postoperative infection.

Blood Transfusion, Autologous↗